UCB SA is a biopharmaceutical company that engages in the research, development and commercialization of innovative drugs in the fields of central nervous system and immunology disorders. The company focuses on the development of innovative medicines. It sells bio-pharmaceutical products for treating central nervous system disorders, immune disorders and allergies and others. The central nervous system disorders which include epilepsy, Parkinson's disease, restless legs syndrome and fibromyalgia; and immunology disorders, namely Crohn's disease, rheumatoid arthritis, lupus, and bone loss disorders. The company was founded in 1928 by Emmanuel Janssen, and is headquartered in Brussels, Belgium.